Clinical Oncology
Volume 20, Issue 5 , Pages 340-344 , June 2008

Prevalence of Overt Metastases in Locally Advanced Breast Cancer

  • H. Al-Husaini

      Affiliations

    • Princess Margaret Hospital, Toronto, Canada
    • ,
  • E. Amir

      Affiliations

    • Princess Margaret Hospital, Toronto, Canada
    • ,
  • B. Fitzgerald

      Affiliations

    • Princess Margaret Hospital, Toronto, Canada
    • ,
  • F. Wright

      Affiliations

    • Toronto Sunnybrook Regional Cancer Centre, Toronto, Canada
    • ,
  • R. Dent

      Affiliations

    • Toronto Sunnybrook Regional Cancer Centre, Toronto, Canada
    • ,
  • J. Fralick

      Affiliations

    • Toronto Sunnybrook Regional Cancer Centre, Toronto, Canada
    • ,
  • M. Clemons

      Affiliations

    • Princess Margaret Hospital, Toronto, Canada
    • Corresponding Author InformationAuthor for correspondence: M. Clemons, Princess Margaret Hospital (Suite 5-205), 610 University Avenue, Toronto, ON M5G 2M9, Canada. Tel: +1-416-946-4534; Fax: +1-416-946-2983.

Received 22 October 2007 ,Revised 6 March 2008 ,Accepted 10 March 2008.

References 

  1. Canadian Cancer Statistics. Available from: www.cancer.ca[accessed 19.10.07]
  2. In:  Greene F,  Page DL,  Fleming ID editor. AJCC cancer staging manual. 6th edn. New York: Springer; 2002;
  3. Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004;22:2303–2312
  4. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676–2685
  5. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–469
  6. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005;23:7098–7104
  7. Myers RE, Johnston M, Pritchard K, Levine M, Oliver T. Breast Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. Baseline staging tests in primary breast cancer: a practice guideline. Can Med Assoc J. 2001;164:1439–1444
  8. Puglisi F, Follador A, Minisini AM, et al. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol. 2005;16:263–266
  9. McWhirter E, Yogendran G, Wright F, Pharm GD, Clemons M. Cancer Care Ontario Practice Guidelines Initiative. Baseline radiological staging in primary breast cancer: impact of educational interventions on adherence to published guidelines. J Eval Clin Pract. 2007;13:647–650
  10. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97:966–975
  11. Mogavero GT, Fishman EK, Kuhlman JE. Inflammatory breast cancer: CT evaluation. Clin Imaging. 1992;16:183–186
  12. Alix-Panabières C, Müller V, Pantel K. Current status in human breast cancer micrometastasis. Curr Opin Oncol. 2007;19:558–563
  13. Landheer ML, Steffens MG, Klinkenbijl JH, Westenberg AH, Oyen WJ. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer. Br J Surg. 2005;92:1363–1367

PII: S0936-6555(08)00147-7

doi: 10.1016/j.clon.2008.03.006

Clinical Oncology
Volume 20, Issue 5 , Pages 340-344 , June 2008

Article Tools